BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21697494)

  • 1. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response.
    Wang E; Kim DY; Weaver SC; Frolov I
    J Virol; 2011 Sep; 85(17):9249-52. PubMed ID: 21697494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
    Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
    J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
    Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
    J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
    Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
    Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections.
    Chattopadhyay A; Aguilar PV; Bopp NE; Yarovinsky TO; Weaver SC; Rose JK
    Vaccine; 2018 Jun; 36(27):3894-3900. PubMed ID: 29807712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
    Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
    J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.
    Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC
    J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric alphavirus vaccine candidates for chikungunya.
    Wang E; Volkova E; Adams AP; Forrester N; Xiao SY; Frolov I; Weaver SC
    Vaccine; 2008 Sep; 26(39):5030-9. PubMed ID: 18692107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective chikungunya virus-like particle vaccine produced in insect cells.
    Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
    PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
    Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.